September 20 2016

The aim of IMI is to improve health by speeding up the development of, and patient access to, innovative medicines. To submit a successful project, you will need to form a consortium consisting of the “key” players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. Then, apply for support in response to an open Call for proposals.

The following topics are under consideration for inclusion in Calls for proposals to be launched in Autumn 2016:

• Understanding hypoglycaemia: the underlying mechanisms and addressing clinical determinants as well as consequences for people with diabetes by combining databases from clinical trials 
• How big data could support better diagnosis and treatment outcomes for prostate cancer 
  • Note: topic forms part of the IMI Big Data for Better Outcomes (BD4BO) programme
• Improving the care of patients suffering from acute or chronic pain 
  • Note: this topic consists of three subtopics:
    • A : Using patient reported outcome measures to improve the management of acute and chronic pain (PROMs)
    • B : Improving the translatability of pharmacodynamic biomarkers in pain pathways of healthy subjects and preclinical species (BIOM)
    • C: Improving translation in chronic pelvic pain (PCC)
• Creation of a pan-European paediatric clinical trials network 
• Biomanufacturing 2020: Development of innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes 
• Unlocking the solute carrier gene-family for effective new therapies 
• Enhanced patient voice in medicines lifecycle
• Precision medicines approaches in autism spectrum disorders 

At ttopstart we are specialised in forming complementary consortia consisting of key players in healthcare with a competitive edge. We serve leading researchers and innovative companies exclusively in the fields of life sciences, medical technology and health in more than 20 European countries and the US and Canada by acquiring funding for cutting-edge research and development. Are you thinking about submitting a proposal to IMI and do you want support in developing a competitive proposal? Feel free to contact us to discuss your possibilities.

All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be communicated after approval by the IMI Governing Board.